Stocks to Buy

Whether you are a novice who just opened your first 401k or you are a seasoned investor, you have to spend countless hours researching stocks to buy. Who has that kind of time? We do. Powered by a diverse group of perspectives formed from dozens of analysts, advisors and strategists, our stories digest the day’s biggest headlines to uncover which stocks you should buy.

7 Stocks to Buy for Bargain Hunters on the Prowl

Wager on these top bargain stocks poised for a comeback, offering both long-term gains and income, away from the growth stock bubble.

Palantir Outlook: 3 Reasons Why Investors Should Be Cautious on PLTR Stock

Palantir reported a stellar Q4 earnings results, but my PLYR stock analysis says fear of "AI hype" should make investors cautious.

7 Monthly Dividend Stocks for Your February Buy List

If you’re retired and looking for your investment portfolio to provide an income stream, the biggest thing you’re looking for is consistency. And that’s what…

7 Terrific Tech Stocks to Buy Instead of the Magnificent 7

Rather than chasing the overvalued Magnificent 7 stocks, investors should focus on high-quality yet overlooked tech stocks.

Profit Migration: 3 Stocks Set to Siphon Investor Dollars From the Magnificent 7

In the stock market, a seismic shift is underway—a combination of three stocks may be going to challenge the status quo of the current Magnificent 7.

INTC Stock Analysis: Why Intel Is Well Worth a Look on Any Pullback

My INTC stock analysis: If chip stocks tank as 'AI mania' takes a breather, this could create a solid entry point for a long-term position.

PYPL Stock Analysis: Wall Street Can’t Agree on PayPal. Buy It Anyway.

My PYPL stock analysis suggests this transitional year won't be easy. Success here means digging in and staying for the long haul.

Surprise! Why Warren Buffet’s Apple Stock Trim Is Actually a Buy Opportunity for Investors.

Here's why long-term growth investors simply can't go wrong buying this company according to the AAPL stock analysis.

Giddy-Up! Why SOFI Stock Deserves to Go Higher.

After reviewing SoFi Technologies' impressive quarterly results, it's surprising that SOFI stock isn't well into the double digits right now.

7 Growth Stocks to Buy Before They Double in 2024

Investors can expect these explosive yet discounted growth stocks to deliver market-crushing returns through 2024 and beyond.

ROIC Rockstars: 3 Stocks to Buy for Long-Term Rewards

The return on invested capital is a metric that doesn’t get enough attention. These ROIC stocks will outperform over the long haul.

Unleash Massive Returns With These 3 Top Penny Stocks

Our economy is doing well, and these top penny stocks are in position to benefit from this. Invest now and see strong returns.

7 Millionaire-Maker Penny Stocks to Buy in February 2024

In general, investors look at penny stocks for trading and speculation. Quick gains are an opportunity for exit and entry into another potentially speculative name.…

Move Over Magnificent 7, Say Hello to the GRANOLAS

Dive into the compelling world of GRANOLAS stocks: Europe's elite players shaping the future of pharmaceuticals, tech, and consumer goods.

The 2 Best and 1 Worst Cryptos to Buy and Sell in 2024

Here are two cryptos to buy, and one to sell, for investors looking for ways to play this rather uncertain crypto market in 2024.

3 Hyper-Growth Stocks to Add Rocket Fuel to Your Portfolio

Do you want to jump-start your portfolio returns? Here are three of the most promising hyper-growth stocks to add to your prospects.

7 Unstoppable Software Stocks Set to Soar in 2024

Multiple overlooked software stocks across various niches hold significant upside potential this year. Consider these seven.

The Best 7 Tech Stocks to Buy for AI Cloud Exposure

Investing in these AI tech stocks provides excellent exposure to growth in 2024 and the remainder of the decade.

3 Biotech Stocks That Could Be Multibaggers in the Making: February Edition

Now could be the time to start looking into these biotech stocks as there are imminent approvals on their clinical trials.